15th December 2015 Content supplied by: Cepheid
Xpert Flu+RSV Xpress is First PCR Panel Test to Achieve CLIA Waiver
The FDA has granted 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for Cepheid's Xpert® Flu+RSV Xpress test for use on the GeneXpert® Xpress™ System.
The GeneXpert Xpress System is a customized GeneXpert System comprised of a single module and a tablet computer with an ATM-like interface specifically for the CLIA waived environment. Xpert Flu+RSV Xpress is the first PCR panel test to achieve CLIA waiver, and the first in a series of reference-quality molecular tests that Cepheid intends to deliver to the point of care market over the next several years.
"There are more than 1 billioni visits annually to physicians' offices in the United States and yet, until recently, CLIA waived testing sites have not had access to the same levels of accuracy found in sophisticated hospital or reference laboratories," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "We believe that point of care testing will be well served by the significant step up in accuracy and multiplexing capability of PCR-based molecular assays and are committed to broadening access to these important tests."
"The Flu+RSV Xpress test uses the same design as our lab-based Flu/RSV XC test, which has already shown in several studiesii,iii to provide performance that meets or exceeds that of other conventional molecular testing run in hospital or reference labs," added David Persing, M.D., Ph.D, Cepheid's Chief Medical and Technology Officer. "Novel design features of this test include high-level multiplexing, redundant target segments, and extended coverage for human and avian influenza strains - a first in the industry for the CLIA waived market and an important step towards pandemic preparedness."
Cepheid's Xpert Flu/RSV XC test has been available for CLIA moderate complexity customers since November 2014. The Xpert Flu+RSV Xpress test utilizes the same test cartridge as the Xpert Flu/RSV XC test and will be available for customers in CLIA-waived settings in December.
Both Cepheid's Xpert Flu/RSV XC and Xpert Flu+RSV Xpress tests detect and differentiate between Influenza A, Influenza B, and RSV, in about one hour.
Date Published: 15th December 2015
Source article link: http://ir.cepheid.com/releasedetail.cfm?ReleaseID=945815